WHO/IGWG

KEI comments to WHO EWG

KEI filed comments with the WHO Expert Working Group. A copy is available here.

Views on the 61st World Health Assembly adoption of Global Strategy on Public Health, Innovation and Intellectual Property

On 24 May 2008, the 61st World Health Assembly, the World Health Organization’s highest governing body, adopted the Global Strategy on Public, Innovation and Intellectual Property. As stated by James Love (Director, Knowledge Ecology International) in his random-bits posting (31 May 2008)

Of fog and thickets: The WHO IGWG process

The WHO IGWG drafting group meeting in Salle XXIII of the Palais des Nations during this week’s World Health Assembly is charged with hammering out a consensus global strategy that would inter alia, secure

an enhanced and sustainable basis for needs-driven, essential health research and development relevant to diseases that disproportinately affect developing countries, proposing clear objectives and priorities for research and development, and estimating funding needs in in this area.

Jon Santamauro, former US trade official now on BIO IGWG delegation

During the IGWG, BIO, the trade association, a group not yet in official relations with the WHO, was given the right to place four persons inside the closed drafting sessions. One of them was Jon Santamauro, who until recently was a US trade official on intellectual property issues.

“Mr. Santamauro has more than 15 years of experience handling intellectual property issues for the U.S. Government.”

Colombian Submission to the WHO IGWG negotiation

By resolution WHA 59.24, the WHO’s Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property (IGWG) has the goal of producing a Global Strategy and Plan of Action that will implement the CIPIH report recommendations and “secure an enhanced and sustainable basis for needs-driven, essential health research and development relevant to diseases that disproportionately affect developing countries, proposing cle

Reasons why the IGWG should not place limits on the scope of diseases

In attempting to address problems of access to medicines in developing countries, it is not productive to utilize any typology to limit the scope of diseases that are to be part of the WHO Global Strategy and Plan of Action’s focus for the next 7 years.

IGWG2 awards

The IGWG Negotiations are coming to the end, and although it is not clear what the package the negotiators will deliver is, enough of the process has been seen to rate the performances of some of the actors.

Mexico’s proposed deletion of consumer rights in the IGWG Text

Tomorrow morning (Friday the 9th), the IGWG finally takes up Element 5, the intellectual property text. These are the deletions to the text being requested by Mexico.

———-
ELEMENT 3

This would include:
building innovative capacity in science and technology and traditional medicine/genetic resources, in agreement with the legislation existing in the Parties on this issues;
rational health-orientated intellectual property management. (Mexico suggest delete)

OECD High Level Forum to lend a boost to WHO IGWG?

The just concluded OECD High Level forum, held June 21 in Noordwijk in the Netherlands is, if it follows the agenda it has set for itself, to give political and perhaps financial impetus to the effort to WHO Intergovernmental Working Group on Public Health, Innovation and Intellectual Property.

OECD high forum, where are the NGO voices?

The OECD High Level Forum to be held in the Netherlands on June 20 and 21, proposes to discuss new policy strategies to stimulate innovation for and access to medicines for neglected diseases. The meeting has on its face very laudable goals. But while NGOs have been invited to the HLF, they have not been given sufficient opportunity to contribute to the discussion Only one NGO has been invited to speak. By contrast other actors from academia and industry have been given multiple opportunities to present their views.

Syndicate content